SGMT Sagimet Biosciences Inc. - Seri
$10.88▼ -1.63%
Healthcare
Other
After hours
$10.88▲ +0.00%
Sep 11, 7:30 PM ET
Volume 639.3K
Avg Volume (10D) 983.7K
Key Metrics & Fundamentals
Market Cap
$676.29M
P/E Ratio
–
Div Yield
–%
52W Range
4.50 - 11.45
% vs 50 MA
21.76%
% vs 200 MA
57.71%
RSI-14
63.4
MACD Histogram
-0.0700
Beta (1Y vs SPY)
2.04
Free Cash Flow
-$11.10M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$15.82M
COGS
–
Operating Exp
$15.82M
Operating Income
-$15.82M
EBIT
-$15.82M
Pretax Income
-$13.95M
Net Income
-$13.95M
EPS (Diluted)
-0.26
Price & Volume History
Loading chart…
Recent News
Cantor Fitzgerald Initiates Coverage on Sagimet Biosciences With Overweight Rating
MT Newswires · Sep 9, 2026 12:06 PM
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8
MT Newswires · Sep 9, 2026 11:41 AM
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 11:00 AM
Sagimet Biosciences Says US Late-Stage Trial of Denifanstat to Treat Acne on Track for Q4 Enrollment
MT Newswires · Aug 25, 2026 11:33 AM
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
GlobeNewswire · Aug 25, 2026 11:00 AM
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 17, 2026 8:28 PM
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
MarketBeat · Aug 17, 2026 8:01 AM
Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial
MT Newswires · Aug 13, 2026 1:12 PM
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
GlobeNewswire · Aug 13, 2026 11:00 AM
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says
MT Newswires · Aug 11, 2026 5:54 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SGMT's money flow as a full page
Social Sentiment
No Reddit posts found for SGMT.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.